Industry Leaders will be available on newsstands April 28. The full list is available now at: https://time.com/article/2026/04/27/time100-companies-health/ About Sprout Pharmaceuticals Sprout Pharmaceuticals is leading a revolution in women's...
of Defense (DoD) and will begin commercial deployment of its FDA-cleared wound treatment, Hemastyl®, starting May 1, 2026. Clinical training across VA and DoD facilities will begin May 1, marking the company's first large-scale entry into...
and spinal cord, at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 11–15, 2026 in Boston, MA. Data presented by Apertura at ASGCT show that TfR1 CapX can be manufactured at clinically relevant scale,...
New Drug Application (sNDA) to the FDA in 2H26 based on the ReSPECT results. Mundipharma expects an EMA submission in Q3, 2026. About rezafungin Rezafungin is a next-generation echinocandin approved for the treatment of candidaemia and invasive...
indication of obesity. Topline data from the Phase II study for the treatment of T2D are expected in the third quarter of 2026. "ASC30 has potential to be the best-in-class oral small molecule GLP-1 for obesity, evidenced by its efficacy and...
with Attenuation in IA TPX-100 Treated Knees" (Poster #665) at the Osteoarthritis Research Society International (OARSI) 2026 World Congress in West Palm Beach, Florida (23 – 26 April 2026). The poster is being presented April 24 – 25. WORMS (Whole...
up to $100,000 and gain access to OSV's network of founders, investors and experts. OSV will award up to 20 fellowships in 2026. Mitchell-Wang is the fourth fellow announced in 2026. More information about previous fellows is available at OSV's...
the layers that drive up costs, you give people more control over how they get their prescriptions.” Beginning April 27, 2026, Eliquis will be available on Cost Plus Drugs, and patients with a prescription will pay a total of $345 for a 30-day...
build upon previously reported one-year results and were presented at the American Association of Clinical Endocrinology 2026 Annual Meeting in Las Vegas. Chronic exposure to supraphysiologic GC doses is associated with cardiometabolic...
that has eluded the field for decades. The program will be featured at leading transplant and virology meetings in 2026, building on findings presented at the ASN in 2025. Alongside its core focus on polyomaviruses, Orthogon is advancing programs...
time spent in the operating room. The AAT XR is expected to be available in the United States early in the second half of 2026, with select geographic expansion planned later this year. The Dynamo Series smart stretcher, the latest innovation in...
13th International Conference on Chemical and Biological Sciences (ICCBS 2026) will be held in Osaka, Japan during, co-sponsored by Network Joint Research Center for Materials and Devices: Dynamic Alliance for Open Innovation Bridging Human,...
of patients with hematologic malignancies. The new Prescription Drug User Fee Act (PDUFA) target action date is July 6, 2026. The extension follows Orca Bio's recent submission of updated chemistry, manufacturing and controls (CMC) information in...
is not required, as would be typical for organ transplants from other donors. Phase 1b/2a Data Presented at AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases Oryon’s lead program is currently being evaluated in an ongoing...
infants are treated with HEMANGEOL annually in the United States. The transaction is expected to be accretive to 2026 earnings and will be financed with the company’s cash on hand. Pierre Fabre will continue commercializing HEMANGEOL globally, and...
and expanding state regulations are dismantling the industry's long-standing "opacity premium." These forces make 2026 more than just another year of policy debate. They mark a structural shift where employer governance and market pressure converge...
(PD-1)/programmed death-ligand 1 (PD-L1) therapy. These data are being presented as a late-breaking oral abstract at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (abstract #LBA417) and are included in...
Confident proteoform characterization and eXd-enabled glycoproteomics on timsOmni The latest version OmniScape™ 2026b strengthens timsOmni proteoform workflows by integrating the novel OmniWave™ algorithm, which enables top-down sequencing and...
with no disease identified on his latest PET conducted 1 month after the administration of the fourth cycle (Feb 2026; Figure 2). Following the first three cycles of 67Cu-SAR-bisPSMA, the participant exhibited mild (Grade 1) related AEs, most of...
-30.0 mL to -50.0 mL).2 PureTech’s Founded Entity, Celea Therapeutics, intends to finalize financing in the first half of 2026 to support the initiation of the Phase 3 SURPASS-IPF trial in the first half of 2026. SURPASS-IPF will compare...
